Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 58
Filtrar
1.
Sci Rep ; 11(1): 425, 2021 01 11.
Artículo en Inglés | MEDLINE | ID: mdl-33432108

RESUMEN

Hypoxia is prevalent in atherosclerotic plaques, promoting plaque aggravation and subsequent cardiovascular disease (CVD). Transmembrane protein carbonic anhydrase IX (CAIX) is hypoxia-induced and can be shed into the circulation as soluble CAIX (sCAIX). As plaque macrophages are hypoxic, we hypothesized a role for CAIX in macrophage function, and as biomarker of hypoxic plaque burden and CVD. As tumor patients with probable CVD are treated with CAIX inhibitors, this study will shed light on their safety profile. CAIX co-localized with macrophages (CD68) and hypoxia (pimonidazole), and correlated with lipid core size and pro-inflammatory iNOS+ macrophages in unstable human carotid artery plaques. Although elevated pH and reduced lactate levels in culture medium of CAIX knock-out (CAIXko) macrophages confirmed its role as pH-regulator, only spare respiratory capacity of CAIXko macrophages was reduced. Proliferation, apoptosis, lipid uptake and expression of pro- and anti-inflammatory genes were not altered. Plasma sCAIX levels and plaque-resident CAIX were below the detection threshold in 50 and 90% of asymptomatic and symptomatic cases, respectively, while detectable levels did not associate with primary or secondary events, or intraplaque hemorrhage. Initial findings show that CAIX deficiency interferes with macrophage metabolism. Despite a correlation with inflammatory macrophages, plaque-resident and sCAIX expression levels are too low to serve as biomarkers of future CVD.


Asunto(s)
Antígenos de Neoplasias/fisiología , Anhidrasa Carbónica IX/fisiología , Enfermedades Cardiovasculares , Macrófagos/metabolismo , Anciano , Animales , Antígenos de Neoplasias/genética , Aterosclerosis/diagnóstico , Aterosclerosis/genética , Aterosclerosis/metabolismo , Biomarcadores/metabolismo , Anhidrasa Carbónica IX/genética , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/metabolismo , Células Cultivadas , Estudios de Cohortes , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados
2.
Acta Virol ; 63(2): 169-185, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31230446

RESUMEN

A rodent-transmitted enveloped lymphocytic choriomeningitis virus (LCMV) is an RNA virus causing persistent infection. During persistent infection, a unique strain MX of LCMV does not yield infectious virions, therefore it is not able to use a receptor for its dissemination, and spreads by cell-to-cell contacts. Virus can be transported to the neighboring cell by different cellular structures such as tunneling nanotubes or cytonemes. Using q-PCR, immunofluorescence, siRNA and western blot, we show that keratin 1 (K1) is essential for the persistent infection caused by LCMV strain MX, and its absence very effectively slows down the course of infection. In contrast, other LCMV strains, namely Clone 13 and Armstrong, which produce expression of K1, desmosomes in cells expressing K1 (42-MG-BA) but not in cells without K1 expression (NIH/3T3). We conclude that the presence of the virus enhances the K1 expression, while the presence of K1 protein potentiates the viral spread in persistently infected cells. Keywords: lymphocytic choriomeningitis virus; keratin 1; persistent infection; desmosomes; virus transport.


Asunto(s)
Queratina-1 , Coriomeningitis Linfocítica , Virus de la Coriomeningitis Linfocítica , Animales , Línea Celular , Regulación de la Expresión Génica , Queratina-1/genética , Coriomeningitis Linfocítica/genética , Virus de la Coriomeningitis Linfocítica/clasificación , Virus de la Coriomeningitis Linfocítica/fisiología , Ratones , Células 3T3 NIH
3.
Acta Virol ; 62(4): 424-434, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30472873

RESUMEN

Lymphocytic choriomeningitis virus (LCMV) can establish in its host a persistent infection, without any prominent symptoms. Even during this infection, when the infectious virions are not released, the virus still disseminates effectively. A very effective and fast way of infection of neighboring cells utilized by many viruses is cell-to-cell transmission. Viruses use different ways of cell-to-cell spread through the extracellular space or by intracellular means through different protrusions. We have found that LCMV strain MX may use three different types of cell-to-cell transport. Firstly, similar to vaccinia virus, it can use actin to propel the virus towards the neighboring cell. Secondly, virus can travel through the intracellular space inside the tunneling nanotubes, that connect the cells even at longer distances and thirdly, the virus may travel on the surface of the membrane of different protrusions connecting two cells. We have also proved that the cells infected by MX strain of LCMV migrate faster than the uninfected cells or cells infected with a different LCMV strain. In accordance with faster migration, the infected cells form more lamellipodia with high expression of keratin 1. In this work, we have introduced three types of cell-to-cell transmission utilized by strain MX of LCMV and showed that even if the cells are not in tight connection, the virus forces them to migrate faster to join the nearest cell. As we show in this work, the virus may use more than one strategy to move to another cell, while each strategy can substitute another. These ways of transmission are very fast and effective and may have a serious impact on the host. Moreover, targeting the cell-to-cell spread, by inhibiting for instance GTPase dynamin, could be an effective way of virus elimination. Keywords: lymphocytic choriomeningitis virus; transmission; migration; keratin 1; nucleoprotein.


Asunto(s)
Coriomeningitis Linfocítica , Virus de la Coriomeningitis Linfocítica , Movimiento Celular , Citoplasma , Células HeLa , Humanos , Coriomeningitis Linfocítica/transmisión , Coriomeningitis Linfocítica/virología
4.
Neoplasma ; 63(6): 836-845, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27565321

RESUMEN

Cancer cells often rely on glycolytic metabolism in order to fulfill high demands of ATP and macromolecules for the sustained growth and proliferation. However, glycolysis is not necessarily the main source of energy for all cancer cells. Some of them rather depend on glutamine or lactate that favor the utilization of oxidative metabolic pathway. Different employment rate of metabolism creates variable products that participate in the formation of environmental milieu, which in turn triggers broad spectrum of cellular signaling pathways leading to migration, invasion, or proliferation. In this review we discuss different metabolic pathways promoted in tumor cells and describe the possibilities of their targeting as therapeutic strategies.


Asunto(s)
Metabolismo Energético , Glucólisis , Neoplasias/metabolismo , Movimiento Celular , Humanos , Invasividad Neoplásica , Transducción de Señal
5.
Neoplasma ; 63(5): 687-95, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27468872

RESUMEN

Renal angiomyolipomas (AMLs) are uncommon benign tumors that occur sporadically or as a part of tuberous sclerosis complex (TSC). Risk of life threatening hemorrhage is the main clinical concern. Although several evidences suggest that hyper-activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway is crucial for these tumors, modulation of other metabolic pathways might affect tumor growth and progression. Therefore, we aimed to further characterize angiomyolipoma by TSC1/TSC2 expression, hypoxic status, expression of endoplasmic reticulum (ER) stress markers and calcium transport from the ER through the inositol 1,4,5-trisphosphate (IP3) receptors. Despite our expectations, angiomyolipoma were not hypoxic, as determined by absent expression of the carbonic anhydrase IX, which is a reliable marker of hypoxia. This was in accord with very low expression of TSC1 (that is associated with HIF activation) and a high expression of TSC2. Angiomyolipoma specimens also showed a significant upregulation of an anti-apoptotic marker Bcl2 when compared to healthy kidney tissue supporting the induction of pro-survival signaling. Moreover, angiomyolipoma specimens showed the overexpression of the ER stress markers XBP1, CHOP and ATF4 as well as of the mediators of calcium metabolism, namely the type 1 and 2, but not the type 3 IP3 receptors. These data suggest that the ER stress response, survival and calcium metabolism-related pathways but not hypoxia is an important component of the angiomyolipoma pathogenesis.


Asunto(s)
Angiomiolipoma/patología , Señalización del Calcio/fisiología , Estrés del Retículo Endoplásmico/fisiología , Receptores de Inositol 1,4,5-Trifosfato/metabolismo , Neoplasias Renales/patología , Factor de Transcripción Activador 4/biosíntesis , Antígenos de Neoplasias/biosíntesis , Anhidrasa Carbónica IX/biosíntesis , Hipoxia de la Célula/fisiología , Humanos , Riñón/patología , Diana Mecanicista del Complejo 1 de la Rapamicina/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Factor de Transcripción CHOP/biosíntesis , Esclerosis Tuberosa/patología , Proteína 1 del Complejo de la Esclerosis Tuberosa/biosíntesis , Proteína 2 del Complejo de la Esclerosis Tuberosa/biosíntesis , Proteína 1 de Unión a la X-Box/biosíntesis
6.
Acta Virol ; 60(2): 143-50, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27265463

RESUMEN

Lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen, which can cause severe illnesses in humans. The most vulnerable are the human foetus and immunosuppressed individuals. Since there is no commercially available enzyme-linked immunosorbent assay (ELISA) for the diagnosis of anti-LCMV antibodies in human sera, we developed a sandwich ELISA method detecting anti-nucleoprotein IgG antibodies, using a specific monoclonal anti-nucleoprotein antibody and cells persistently infected with LCMV strain MX as antigen. In the present study we show standardization of this ELISA protocol, determination of its clinical specificity and sensitivity and its application on 30 clinical samples from multiorgan donors. Comparison of these results to the indirect immunofluorescence antibody test (IFA) demonstrates that ELISA is more sensitive. The developed ELISA assay provides a fast, simple and efficient tool for the clinical detection of anti-nucleoprotein antibodies in human sera.


Asunto(s)
Anticuerpos Antivirales/análisis , Ensayo de Inmunoadsorción Enzimática/métodos , Inmunoglobulina G/análisis , Coriomeningitis Linfocítica/diagnóstico , Virus de la Coriomeningitis Linfocítica/aislamiento & purificación , Anticuerpos Antivirales/inmunología , Humanos , Inmunoglobulina G/inmunología , Coriomeningitis Linfocítica/inmunología , Coriomeningitis Linfocítica/virología , Virus de la Coriomeningitis Linfocítica/inmunología
7.
Bratisl Lek Listy ; 117(4): 201-4, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27075382

RESUMEN

OBJECTIVES: The objective of the study was to investigate prognostic and predictive value of pretreatment soluble carbonic anhydrase IX (CA IX) blood serum concentration in patients with locally advanced head and neck cancer. BACKGROUND: Increased expression of CA IX in tumor tissues has been associated with treatment resistance and worth prognosis. Soluble form of CA IX, released from tumor cells, is detectable in blood serum and could be a convenient predictive factor of treatment effectiveness that would enable treatment individualization. METHODS: The prospective study evaluated 48 patients with locally advanced squamous cell carcinomas of head and neck, treated by radiotherapy or chemo-radiotherapy. Pretreatment soluble CA IX serum concentrations were examined using enzyme-linked immunosorbent assay. RESULTS: Soluble CA IX serum concentration failed to predict radiotherapy effectiveness in the studied patient population (p = 0.26). However, high CA IX serum concentrations have been associated with shorter overall survival (p = 0.035) CONCLUSION: High pretreatment CA IX serum concentration is a negative prognostic factor in locally advanced head and neck cancer patients (Tab. 1, Fig. 2, Ref. 23).


Asunto(s)
Antígenos de Neoplasias , Anhidrasas Carbónicas , Carcinoma de Células Escamosas , Quimioradioterapia/métodos , Neoplasias de Cabeza y Cuello , Anciano , Antígenos de Neoplasias/análisis , Antígenos de Neoplasias/sangre , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/sangre , Anhidrasa Carbónica IX , Anhidrasas Carbónicas/análisis , Anhidrasas Carbónicas/sangre , Carcinoma de Células Escamosas/sangre , Carcinoma de Células Escamosas/mortalidad , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/terapia , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Neoplasias de Cabeza y Cuello/sangre , Neoplasias de Cabeza y Cuello/mortalidad , Neoplasias de Cabeza y Cuello/patología , Neoplasias de Cabeza y Cuello/terapia , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Estudios Prospectivos , Reproducibilidad de los Resultados , Eslovaquia , Carcinoma de Células Escamosas de Cabeza y Cuello , Análisis de Supervivencia , Resultado del Tratamiento
8.
Acta Virol ; 60(1): 15-26, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26982463

RESUMEN

Lymphocytic choriomeningitis virus (LCMV) is a prototype virus of the Arenaviridae family that is attracting considerable attention both as an important experimental model system to study acute and persistent viral infections, and as a neglected human pathogen of clinical significance. Notably, LCMV is capable of persisting in an infected host, and escaping the immune system. Here we describe the strategies used by the virus to establish and maintain long-term infection in vitro and/or persistent infection in vivo. We discuss how the viral components (RNA, nucleoprotein, glycoprotein, Z protein) manipulate the host cell machinery to facilitate survival and spread of the virus without disturbing the basal cellular processes. Deep understanding of these strategies is inevitable for the development of approaches towards restricting the virus spread and/or preventing its harmful reactivation. This review summarizes the current status in this area and presents ideas emerging from existing data.


Asunto(s)
Coriomeningitis Linfocítica/virología , Virus de la Coriomeningitis Linfocítica/fisiología , Animales , Humanos , Virus de la Coriomeningitis Linfocítica/genética
9.
Neoplasma ; 63(2): 183-92, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26774137

RESUMEN

Endosialin, alternatively named tumor endothelial marker 1 (TEM1) or CD248, is a bulk transmembrane glycoprotein expressed both in developing and adult tissues undergoing active physiological or pathological angiogenesis. Endosialin is often overexpressed in tumors, particularly in stromal cells and in vessels-covering pericytes, and its transcription is induced by hypoxia via HIF-2 transcription factor. Based on the expression pattern, molecular characteristics and phenotypes of genetic models, endosialin has been proposed to function as a receptor implicated in sprouting angiogenesis, vasculogenesis and/or pruning of vessels. Here we provide an overview of the recent knowledge linking endosialin to diverse aspects of angiogenesis. Based on data-mining, our experimental data and available literature, we suggest that endosialin cross-talks with both pro- and anti-angiogenic signals and ECM components, and participates in dynamic vascular remodeling, which facilitates tumor growth. Tumor-selective targeting of endosialin may therefore contribute to improvement of existing anti-angiogenic therapies.


Asunto(s)
Antígenos CD/biosíntesis , Antígenos CD/metabolismo , Antígenos de Neoplasias/biosíntesis , Antígenos de Neoplasias/metabolismo , Endotelio Vascular/metabolismo , Proteínas de Neoplasias/biosíntesis , Neoplasias/patología , Neovascularización Patológica/patología , Antígenos CD/genética , Antígenos de Neoplasias/genética , Secuencia de Bases , Hipoxia de la Célula/fisiología , Humanos , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Neoplasias/irrigación sanguínea , Pericitos/metabolismo
10.
Klin Onkol ; 28(3): 183-90, 2015.
Artículo en Checo | MEDLINE | ID: mdl-26062620

RESUMEN

Oxygen is absolutely essential for correct functioning of living organisms and alterations in its concentration lead to serious consequences. In tumor tissues, oxygen plays an important role in energy production and modulation of red- ox balance. Insufficient oxygen supply within tissues results in hypoxia that is a characteristic feature of the tumor microenvironment. Hypoxia- inducible transcriptional factor represents a key executor of a cellular and molecular response to hypoxia and can activate the expression of more than hundred genes involved in various essential cellular processes. From the clinical point of view, phenotypic alterations caused by hypoxia are serious. Tumor hypoxia has been associated with resistance to therapy, disease progression and recurrence as well as increased mortality. Therefore, intratumoral hypoxia represents a clinically relevant problem, and its detection within tumors is very important for patient stratification for a suitable treatment. Currently available strategies directed towards the detection of hypoxic regions within tumor tissue suffer from numerous limitations e. g. invasiveness, inaccessibility of tumor tissue, low sensibility, inaccurate interpretation etc. On the other hand, the use of an intrinsic endogenous hypoxic marker, which can be detected through immunohistochemistry, is relatively simple, routinely available, and reproducible and can be performed on both prospective and retrospective samples. These include carbonic anhydrase IX (CA IX), one of the most strongly hypoxia-induced proteins and a prominent indicator of chronic hypoxia. Moreover, hypoxia-induced proteins (including CA IX) are also potential targets of anticancer therapy, and their practical application is a subject of intense research.


Asunto(s)
Biomarcadores de Tumor/biosíntesis , Hipoxia de la Célula/fisiología , Proteínas de Neoplasias/biosíntesis , Oxígeno/metabolismo , Antígenos de Neoplasias , Biomarcadores de Tumor/análisis , Anhidrasa Carbónica IX , Anhidrasas Carbónicas , Humanos , Microambiente Tumoral
11.
Klin Onkol ; 27(4): 269-75, 2014.
Artículo en Checo | MEDLINE | ID: mdl-25115716

RESUMEN

BACKGROUND: Hypoxia of locally advanced head and neck cancers is one of the main causes of their radiation resistance that presents clinically as a persistence of residual tumor disease after radiation therapy. Therefore, detection of tumor hypoxia could be an important predictor of treatment efficacy. Carbonic anhydrase IX (CA IX) is a protein, coded by a homonymous gene, the expression of which increases in tumor tissues at hypoxic conditions. Hence, CA IX represents an endogenic marker of tumor hypoxia, identifiable in tumor tissues, and its soluble extracellular domain can also be detected in body fluids of the patient. The primary endpoint of this study was to explore whether a correlation exists between CA IX serum level and the residual tumor disease after therapy. The secondary endpoint was to find out how the serum concentration of CA IX changes during the course of fractionated radiation therapy. MATERIALS AND METHODS: The presented prospective monocentric clinical study evaluated a population of 30 patients with locally advanced squamous cell head and neck cancers, treated by radiation therapy or concurrent chemo radiation therapy with a curative intent. The serum concentration of the soluble form of CA IX was examined from a venous blood sample, using sandwich enzyme linked immunosorbent assay (ELISA). The blood samples were obtained before the treatment initiation, in the middle of radiation therapy, at the time of finishing radiation therapy and six weeks after the treatment completion. RESULTS: We found a substantial variability in the CA IX levels measured in the examined population, ranging 0- 1,696 pg/ ml. We found no significant changes in the mean value of CA IX concentration during the course of radiation therapy and after the treatment completion. In 11 patients (36.7%), the treatment resulted in complete remission of the disease. In these patients, lower average pretreatment levels of CA IX were noted when compared to patients with persistence of residual tumor disease (37.57 vs 77.47; p = 0.154). CONCLUSION: The results indicate that serum level of CA IX in patients with locally advanced head and neck cancers does not change significantly during the course of fractionated radiation therapy. The relation between CA IX serum level and residual tumor disease after radiation therapy requires verification on a larger population of patients.


Asunto(s)
Antígenos de Neoplasias/sangre , Biomarcadores de Tumor/sangre , Anhidrasas Carbónicas/sangre , Carcinoma de Células Escamosas/radioterapia , Hipoxia de la Célula , Neoplasias de Cabeza y Cuello/enzimología , Neoplasias de Cabeza y Cuello/radioterapia , Tolerancia a Radiación , Anhidrasa Carbónica IX , Carcinoma de Células Escamosas/enzimología , Carcinoma de Células Escamosas/patología , Neoplasias de Cabeza y Cuello/patología , Humanos , Neoplasia Residual , Estudios Prospectivos , Inducción de Remisión
12.
Acta Virol ; 57(2): 160-70, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23600874

RESUMEN

Lymphocytic choriomeningitis virus (LCMV) attracts significant attention both as an important experimental model system to study acute and persistent viral infections, and as a neglected human pathogen of clinical significance. This review focuses on the basic aspects and recent advances in the molecular and cell biology of LCMV, the outcome of LCMV infection on its natural host with an emphasis on persistent infection and the outcome of LCMV infection in humans. Lastly, we summarize our contribution to current knowledge on LCM virus.


Asunto(s)
Coriomeningitis Linfocítica/virología , Virus de la Coriomeningitis Linfocítica/fisiología , Animales , Humanos , Virus de la Coriomeningitis Linfocítica/genética , Virus de la Coriomeningitis Linfocítica/metabolismo , Virus de la Coriomeningitis Linfocítica/patogenicidad
13.
Acta Virol ; 57(2): 257-64, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23600882

RESUMEN

Carbonic anhydrase IX (CA IX) is a cell surface protein frequently present in human tumors but not in the corresponding normal tissues. Expression of CA IX is primarily determined by the strong transcriptional activation of the gene encoding CA IX by hypoxia via the hypoxia-inducible transcription factor HIF-1. However, the ultimate abundance of the CA IX protein on the cell surface can be affected by additional mechanisms, including ectodomain shedding and endocytosis. In this paper, we summarize the basic knowledge on how these processes modulate CA IX expression at the post-translational level. We propose that the regulation of the CA IX protein residence in the plasma membrane can influence its biological function as well as its clinical exploitation.


Asunto(s)
Anhidrasas Carbónicas/genética , Anhidrasas Carbónicas/metabolismo , Endocitosis/genética , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Animales , Membrana Celular/enzimología , Membrana Celular/genética , Membrana Celular/metabolismo , Humanos , Isoenzimas/genética , Isoenzimas/metabolismo , Neoplasias/enzimología , Neoplasias/genética , Neoplasias/metabolismo
14.
Acta Virol ; 56(4): 271-82, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23237083

RESUMEN

In this review we discuss existing as well as new approaches to immunotherapy directed against infected or cancerous cells. These approaches traditionally exploit either natural components of immune system (such as cytokines, chemokines, co-stimulatory molecules and adjuvants), or monoclonal antibodies designed to target foreign agents and/or diseased cells through their molecular markers. Additional strategies in development include therapeutic vaccines, oncolytic viruses and T-cell therapies. In addition, we briefly describe a novel strategy called ReDIT (Re-Directed ImmunoTherapy), based on re-orienting the existing long-lasting immune responses (e.g. induced by measles vaccination or natural infection) towards new target molecules on the surface of infected or malignant cells. This can be principally achieved by using bi-functional protein constructs that contain an antigen carrier component and a re-directing component. The antigen carrier component can consist of the ectodomain of the measles hemagglutinin that can be recognized by antibodies and memory cells generated during previous infection or vaccination. The re-directing component consists of the specific virus- or tumor antigen-binding molecule. The fusion constructs are expected to boost existing anti-measles immunity and re-direct it against a new target, engaging the existing anti-measles immunity as an effector mechanism. Thus, ReDIT is a promising novel approach that may represent a valuable addition to immunotherapy of difficult to treat infections and tumors, as it exploits a mechanism distinct from other available therapies.


Asunto(s)
Inmunoterapia/métodos , Neoplasias/terapia , Virosis/terapia , Animales , Antígenos de Neoplasias/inmunología , Antígenos Virales/inmunología , Antivirales/inmunología , Antivirales/uso terapéutico , Humanos , Neoplasias/inmunología , Virosis/inmunología
15.
Acta Virol ; 54(4): 231-45, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-21175245

RESUMEN

Toll-like receptors (TLRs) are members of the innate immunity system. They are responsible for the recognition of various antigens and take part in the modulation of immunity responses. In general, they are divided into "bacterial" and "viral" TLRs, even though this classification overlaps in some cases. Genetic similarity of TLRs gives them the status of highly conservative proteins throughout the animal kingdom. However, there is a certain level of variation between different species that can result in semi-disparate recognition ability. Furthermore, their universal signaling pathways predispose them not only as a target for vaccination trials in humans, but also for the genetic selection in veterinary medicine. Moreover, the selection pressure and their conservative properties make them a suitable system for the evolutionary studies, since each separate genetic system has its own unique ortholog/paralog. TLRs 2, 3, 4, 7, 8, and 9 play a crucial role in the recognition and modulation of the innate immunity in response to the viral infection due to their predominant localization on the white blood cells and endothelial cells, while intracellularly localized TLRs lead the way.


Asunto(s)
Receptores Toll-Like/inmunología , Virosis/inmunología , Animales , Humanos , Inmunidad Innata , Receptores Toll-Like/química , Receptores Toll-Like/genética , Virosis/genética , Virosis/virología
16.
Br J Cancer ; 103(10): 1571-9, 2010 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-20978507

RESUMEN

PURPOSE: Tumour hypoxia activates hypoxia-inducible factor-1 (HIF-1) and indluences angiogenesis, cell survival and invasion. Prolyl hydroxylase-3 (PHD3) regulates degradation of HIF-1α. The effects of PHD3 in tumour growth are largely unknown. EXPERIMENTAL DESIGN: PHD3 expression was analysed in human pancreatic cancer tissues and cancer cell lines by real-time quantitative PCR and immunohistochemistry. PHD3 overexpression was established by stable transfection and downregulation by short interfering RNA technology. VEGF was quantified by enzyme-linked immunosorbent assay. Matrigel invasion assays were performed to examine tumour cell invasion. Apoptosis was measured by annexin-V staining and caspase-3 assays. The effect of PHD3 on tumour growth in vivo was evaluated in an established orthotopic murine model. RESULTS: PHD3 was upregulated in well-differentiated human tumours and cell lines, and regulated hypoxic VEGF secretion. PHD3 overexpression mediated tumour cell growth and invasion by induction of apoptosis in a nerve growth factor-dependent manner by the activation of caspase-3 and phosphorylation of focal adhesion kinase HIF-1 independently. In vivo, PHD3 inhibited tumour growth by abrogation of tumour angiogenesis. CONCLUSION: Our results indicate essential functions of PHD3 in tumour growth, apoptosis and angiogenesis and through HIF-1-dependent and HIF-1-independent pathways.


Asunto(s)
Dioxigenasas/genética , Neovascularización Patológica/patología , Neoplasias Pancreáticas/patología , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Animales , Anexina A5/análisis , Apoptosis , Carcinoma Ductal Pancreático/enzimología , Carcinoma Ductal Pancreático/patología , Carcinoma Ductal Pancreático/cirugía , Caspasa 3/metabolismo , Diferenciación Celular , Línea Celular Tumoral , Dioxigenasas/fisiología , Ensayo de Inmunoadsorción Enzimática , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/fisiología , Prolina Dioxigenasas del Factor Inducible por Hipoxia , Ratones , Invasividad Neoplásica/genética , Invasividad Neoplásica/patología , Neoplasias Pancreáticas/enzimología , Neoplasias Pancreáticas/cirugía , Reacción en Cadena de la Polimerasa , ARN Mensajero/genética , ARN Neoplásico/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Trasplante Heterólogo , Regulación hacia Arriba , Factor A de Crecimiento Endotelial Vascular/análisis
17.
Curr Pharm Des ; 16(29): 3255-63, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20819068

RESUMEN

Carbonic anhydrase IX (CA IX) is a suitable target for various anticancer strategies. It is a cell surface protein that is present in human tumors, but not in the corresponding normal tissues. Expression of CA IX is induced by hypoxia and correlates with cancer prognosis in many tumor types. Moreover, CA IX is functionally implicated in cancer progression as a pro-survival factor protecting cancer cells against hypoxia and acidosis via its capability to regulate pH and cell adhesion. Cancer-related distribution of CA IX allows for targeting cancer cells by antibodies binding to its extracellular domain, whereas functional involvement of CA IX opens the possibility to hit cancer cells by blocking their adaptation to physiologic stresses via inhibition of CA IX enzyme activity. The latter strategy is recently receiving considerable attention and great efforts are made to produce CA IX-selective inhibitor derivatives with anticancer effects. On the other hand, targeting CA IX-expressing cells by immunotherapy has reached clinical trials and is close to application in treatment of renal cell carcinoma patients. Nevertheless, development and characterization of new CA IX-specific antibodies is still ongoing. Here we describe a mouse monoclonal antibody VII/20 directed to catalytic domain of CA IX. We show that upon binding to CA IX, the VII/20 MAb undergoes efficient receptor-mediated internalization, which is a process regulating abundance and signaling of cell surface proteins and has considerable impact on immunotherapy. We evaluated biological properties of the MAb and demonstrated its capacity to elicit anti-cancer effect in mouse xenograft model of colorectal carcinoma. Thus, the VII/20 MAb might serve as a tool for preclinical studies of immunotherapeutic strategies against non-RCC tumors. These have not been explored so far and include broad spectrum of cancer types, treatment of which might benefit from CA IX-mediated targeting.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos de Neoplasias/inmunología , Antineoplásicos/uso terapéutico , Inhibidores de Anhidrasa Carbónica/uso terapéutico , Anhidrasas Carbónicas/inmunología , Dominio Catalítico/inmunología , Neoplasias Colorrectales/tratamiento farmacológico , Terapia Molecular Dirigida/métodos , Animales , Antineoplásicos/farmacología , Anhidrasa Carbónica IX , Inhibidores de Anhidrasa Carbónica/farmacología , Humanos , Ensayos Antitumor por Modelo de Xenoinjerto/métodos
18.
Br J Cancer ; 99(8): 1348-56, 2008 Oct 21.
Artículo en Inglés | MEDLINE | ID: mdl-18813310

RESUMEN

Endosialin is a transmembrane glycoprotein selectively expressed in blood vessels and stromal fibroblasts of various human tumours. It has been functionally implicated in angiogenesis, but the factors that control its expression have remained unclear. As insufficient delivery of oxygen is a driving force of angiogenesis in growing tumours, we investigated whether hypoxia regulates endosialin expression. Here, we demonstrate that endosialin gene transcription is induced by hypoxia predominantly through a mechanism involving hypoxia-inducible factor-2 (HIF-2) cooperating with the Ets-1 transcription factor. We show that HIF-2 activates the endosialin promoter both directly, through binding to a hypoxia-response element adjacent to an Ets-binding site in the distal part of the upstream regulatory region, and indirectly, through Ets-1 and its two cognate elements in the proximal promoter. Our data also suggest that the SP1 transcription factor mediates responsiveness of the endosialin promoter to high cell density. These findings elucidate important aspects of endosialin gene regulation and provide a rational frame for future investigations towards better understanding of its biological significance.


Asunto(s)
Antígenos CD/genética , Antígenos CD/metabolismo , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/metabolismo , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Hipoxia de la Célula/fisiología , Regulación de la Expresión Génica/fisiología , Western Blotting , Línea Celular Tumoral , Humanos , Inmunoprecipitación , Regiones Promotoras Genéticas , Proteína Proto-Oncogénica c-ets-1/metabolismo , Interferencia de ARN , Elementos Reguladores de la Transcripción , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Transcripción Sp1/metabolismo , Transcripción Genética , Transfección , Regulación hacia Arriba
19.
Curr Pharm Des ; 14(7): 685-98, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18336315

RESUMEN

Cells of the growing tumor tissue are exposed to physiological stresses connected with insufficient delivery of oxygen (hypoxia) and accumulation of acidic products of the glycolytic metabolism (acidosis). Adaptation to these microenvironmental stresses involves remodeling of the cellular expression program mediated by hypoxia-inducible factor (HIF), which activates broad array of genes functionally involved in angiogenesis, anaerobic glycolysis, de-adhesion, invasion etc. This leads to increased aggressiveness of tumors, metastatic spread and poor response to therapy. Genes coding for transmembrane carbonic anhydrase (CA) isoforms IX and XII are induced in response to low oxygen as a part of the hypoxic transcriptome. Moreover, CA IX is a direct target of HIF and serves as a surrogate marker of hypoxia and prognostic indicator. Its expression is strongly linked to different types of tumors with the HIF pathway activated due to genetic defect or physiological hypoxia. CA IX (and possibly also CA XII) is participates in pH regulation, which is important for survival of hypoxic cells. Both enzymes are therefore promising therapeutic molecules targetable by inhibitors of CA activity. Some of these sulfonamide compounds and their derivatives are capable to block CA-mediated pH regulation in hypoxia. This review summarizes research data related to distribution, regulation and functional aspects of CA IX and CA XII, and describes emerging possibilities for clinical exploitation of CA inhibitors as imaging tools and anticancer drugs.


Asunto(s)
Antígenos de Neoplasias/metabolismo , Inhibidores de Anhidrasa Carbónica/uso terapéutico , Anhidrasas Carbónicas/metabolismo , Neoplasias/enzimología , Animales , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Anhidrasa Carbónica IX , Inhibidores de Anhidrasa Carbónica/farmacocinética , Hipoxia de la Célula/efectos de los fármacos , Humanos , Concentración de Iones de Hidrógeno , Neoplasias/tratamiento farmacológico , Neoplasias/patología
20.
Br J Cancer ; 98(1): 129-36, 2008 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-18026188

RESUMEN

CA IX is a hypoxia-induced, cancer-associated carbonic anhydrase isoform with functional involvement in pH control and cell adhesion. Here we describe an alternative splicing variant of the CA9 mRNA, which does not contain exons 8-9 and is expressed in tumour cells independently of hypoxia. It is also detectable in normal tissues in the absence of the full-length transcript and can therefore produce false-positive data in prognostic studies based on the detection of the hypoxia- and cancer-related CA9 expression. The splicing variant encodes a truncated CA IX protein lacking the C-terminal part of the catalytic domain. It shows diminished catalytic activity and is intracellular or secreted. When overexpressed, it reduces the capacity of the full-length CA IX protein to acidify extracellular pH of hypoxic cells and to bind carbonic anhydrase inhibitor. HeLa cells transfected with the splicing variant cDNA generate spheroids that do not form compact cores, suggesting that they fail to adapt to hypoxic stress. Our data indicate that the splicing variant can functionally interfere with the full-length CA IX. This might be relevant particularly under conditions of mild hypoxia, when the cells do not suffer from severe acidosis and do not need excessive pH control.


Asunto(s)
Empalme Alternativo , Antígenos de Neoplasias/genética , Biomarcadores de Tumor/genética , Anhidrasas Carbónicas/genética , Hipoxia/genética , Neoplasias/genética , Antígenos de Neoplasias/metabolismo , Biomarcadores de Tumor/metabolismo , Anhidrasa Carbónica IX , Inhibidores de Anhidrasa Carbónica/farmacología , Anhidrasas Carbónicas/metabolismo , Células Cultivadas , Humanos , Hipoxia/metabolismo , Immunoblotting , Inmunoprecipitación , Neoplasias/enzimología , Neoplasias/patología , Fenotipo , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Transfección , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...